Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
M. Kato (Tokyo, Japan), A. Miyamoto (Tokyo, Japan), S. Izumi (Tokyo, Japan), M. Inomata (Tokyo, Japan), K. Kamio (Tokyo, Japan), H. Sumikawa (Osaka, Japan), R. Egashira (Saga, Japan), H. Sugiura (Tokyo, Japan), J. Araya (Tokyo, Japan), M. Takeuchi (Tokyo, Japan), K. Takahashi (Tokyo, Japan), A. Azuma (Tokyo, Japan)
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kato (Tokyo, Japan), A. Miyamoto (Tokyo, Japan), S. Izumi (Tokyo, Japan), M. Inomata (Tokyo, Japan), K. Kamio (Tokyo, Japan), H. Sumikawa (Osaka, Japan), R. Egashira (Saga, Japan), H. Sugiura (Tokyo, Japan), J. Araya (Tokyo, Japan), M. Takeuchi (Tokyo, Japan), K. Takahashi (Tokyo, Japan), A. Azuma (Tokyo, Japan). Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study. 466
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002
Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021 Year: 2022
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018
Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study Source: Eur Respir J 2012; 39: 772-775 Year: 2012
Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial Source: Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020 Year: 2021
Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019
Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study Source: ERJ Open Res, 3 (4) 00100-2017; 10.1183/23120541.00100-2017 Year: 2017
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020
The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies Source: Eur Respir J, 51 (6) 1800376; 10.1183/13993003.00376-2018 Year: 2018
A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007